Pleiotropic effects of statins: How important are they in the prevention of vascular disease?

Endothelium: Journal of Endothelial Cell Research

Volumn 10, Issue 1, 2003, Pages 3-4

  Mehta, J L ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; RAB PROTEIN; RAC PROTEIN; RAL PROTEIN; RAP PROTEIN; RAS PROTEIN; RHO FACTOR; SIMVASTATIN;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ENDOTHELIUM; HEART INFARCTION; HUMAN; ISOPRENYLATION; NONHUMAN; OXIDATION; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; THROMBOGENESIS; VASCULAR DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; OXIDATIVE STRESS; PROTEIN ISOPRENYLATION; RAS PROTEINS; RECEPTORS, LDL; RECEPTORS, OXIDIZED LDL; RHO GTP-BINDING PROTEINS; SCAVENGER RECEPTORS, CLASS E;

EID: 0037235657     PISSN: 10623329     EISSN: None     Source Type: Journal    
DOI: 10.1080/10623320303354     Document Type: Editorial

References (13)

1. Chen L., Haught W.H., Yang B., Saldeen T.G., Parathasarathy S., and Mehta J.L. (1997) Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. Journal of the American College of Cardiology, 30, 569-575.
2. Crouse J.R., Byinton R.P. and Furbert C.D. (1998) HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data. Atherosclerosis, 138, 11-24.
3. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto A.M. Jr. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association, 279, 1615-1622.
4. Heart Protection Study Collaborative Group. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7-22.
5. Laufs U., Marra D., Node K., and Liao J.K. (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). Journal of Biological Chemistry, 274, 21926-21931.
6. Libby P., Sukhova G., Lee R.T., and Liao J.K. (1997) Molecular biology of atherosclerosis. International Journal of Cardiology, 62, S23-S29.
7. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349-1357.
8. Mehta J.L., and Li D. (2002) Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. Journal of the American College of Cardiology, 39, 1429-1435.
9. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., and Gutierrez G. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science, 286, 1946-1949.
10. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and recurrent events trial investigators. New England Journal of Medicine, 335, 1001-1009.
11. Scandinavian Simvastin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
12. Singh R., Wang B., Shirvaikar A., Khan S., Kamat S., Schelling J.R., Konieczkowski M., and Sedor J.R. (1999) The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. Journal of Clinical Investigation, 103, 1561-1570.
13. Weitz-Schmidt G, Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Medicine, 7, 687-692.